CXCR3 and chronic myelomonocytic leukemia: We noted a significantly decreased frequency of cells within cluster 1 in samples from patients with LR-MDS and HR-MDS compared with AML and CMML (Fig. 2B), a cluster that included terminal effector cells (CCR7−CD45RA+) expressing CD57 and CXCR3 (Fig. 2C).